ARCHIVE

• DIAGNOSTIC NEWS IN BRIEF
  June 23, 2003

• OTC NEWS IN BRIEF
  June 23, 2003

• RESEARCH & DEVELOPMENT NEWS IN BRIEF
  June 23, 2003

• REGULATORY NEWS IN BRIEF -2-
  June 23, 2003

• REGULATORY NEWS IN BRIEF　-1-
  June 23, 2003

• New Drug Information Supply System to Be Strengthened
  June 23, 2003

• 8 Ingredients Including New Kits Added to NHI List
  June 23, 2003

• Aiming to Reduce Costs by \10 Billion: Mr Kobori of Mitsubishi Pharma
  June 23, 2003

• Teijin Pharma to Be Firmly Set Up: Mr Ohyagi
  June 23, 2003

• Current NHI Pricing Rule's Perfection Level Is High: Mr Yashiro
  June 23, 2003

• Meiji, Solvay File for Social Anxiety as New Indication for SSRI Fluvoxamine
  June 23, 2003

• AnGes MG Licenses NF-κB Decoy to Goodman
  June 16, 2003

• Matsumotokiyoshi Plans to Acquire Makers
  June 16, 2003

• FJPWA's Future Vision for Drug Wholesale Industry Announced
  June 16, 2003

• Problems with "Health Foods" Pointed Out: Korosho Task Force
  June 16, 2003

• Banyu to Contain Impact of Generics on Lipovas Sales to Less than 10%
  June 16, 2003

• OTC NEWS IN BRIEF
  June 16, 2003

• VITAL-NET to Build Medical Devices/Reagents Network
  June 16, 2003

• Listed Wholesalers' Combined Sales Up 7.2%, Net Profits Up 111.4%
  June 16, 2003

• Antihyperlipidemics Finds High Support for Mevalotin: Epoka's Survey
  June 16, 2003

ページ

• « 先頭
• ‹ Prev
• …
• 591
• 592
• 593
• 594
• 595
• 596
• 597
• 598
• 599
• …
• Next ›
• 最終 »